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A B S T R A C T
Objective. Multicenter longitudinal outcome data for Fontan patients surviving into adulthood are lacking. The aim
of this study was to better understand contemporary outcomes in Fontan survivors by collecting follow-up data in
a previously well-characterized cohort.
Design. Baseline data from the Fontan Cross-Sectional Study (Fontan 1) were previously obtained in 546 Fontan
survivors aged 11.9 ± 3.4 years. We assessed current transplant-free survival status in all subjects 6.8 ± 0.4 years after
the Fontan 1 study. Anatomic, clinical, and surgical data were collected along with socioeconomic status and access
to health care.
Results. Thirty subjects (5%) died or underwent transplantation since Fontan 1. Subjects with both an elevated
(>21 pg/mL) brain natriuretic peptide and a lowChild Health Questionnaire physical summary score (<44) measured
at Fontan 1 were signiﬁcantly more likely to die or undergo transplant than the remainder, with a hazard ratio of 6.2
(2.9–13.5). Among 516 Fontan survivors, 427 (83%) enrolled in this follow-up study (Fontan 2) at 18.4 ± 3.4 years of
age. Although mean scores on functional health status questionnaires were lower than the general population, in-
dividual scores were within the normal range in 78% and 88%of subjects for the ChildHealthQuestionnaire physical
and psychosocial summary score, and 97% and 91% for the SF-36 physical and mental aggregate score, respectively.
Since Fontan surgery, 119 (28%) had additional cardiac surgery; 55% of these (n = 66) in the interim between Fontan
1 and Fontan 2. A catheter intervention occurred in 242 (57%); 32% of these (n = 78) after Fontan 1. Arrhythmia
requiring treatment developed in 118 (28%) after Fontan surgery; 58% of these (n = 68) since Fontan 1.
Conclusions. We found 95% interim transplant-free survival for Fontan survivors over an average of 7 years of
follow-up. Continued longitudinal investigation into adulthood is necessary to better understand the determinants
of long-term outcomes and to improve functional health status.
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Introduction
The Fontan procedure results in near-normalsystemic oxygen saturation in those born
with a functional single ventricle, reducing the
demands on the systemic ventricle and extending
the lives of patients with even the most complex
forms of congenital heart disease. Nevertheless,
the resulting abnormal hemodynamic state is asso-
ciated with a variety of late complications includ-
ing decreased exercise performance, abnormal
ventricular function, intracardiac and extracardiac
thrombosis and embolic phenomena, arrhythmias
and conduction system impairment, cirrhosis, and
protein-losing enteropathy.1–4 As these patients
age into adulthood, access to specialized health
care may become limited as a result of insufﬁcient
insurance, lack of employment, and lack of educa-
tion about the need for evaluation by adult con-
genital heart physicians.5,6 Therefore, although
the survival of children and adolescents with the
Fontan procedure continues to improve, survivors
remain at increased risk for mortality and morbidi-
ties, as well as physiologic limitations that are
likely to impact physical, psychological, and socio-
economic status.7,8
The Pediatric Heart Network Fontan Cross-
Sectional Study (Fontan 1) characterized a multi-
institutional cohort of 546 survivors after the
Fontan procedure, with an age of 6 to 18 years at
enrollment in 2003–2004.9 The design of Fontan 1
could not determine if observed differences
between older and younger subjects were related
to the length of time living with Fontan physiol-
ogy or to changes in medical, catheter-based, or
surgical management strategies. The primary
objective of the current study (Fontan 2) was to
better understand contemporary outcomes in
Fontan survivors by collecting follow-up data
involving assessment of vital status, repeat func-
tional health status, collection of interim medical
history, and access to health care at an average of 7
years after enrollment in Fontan 1.
Methods
Study Design and Patient Population
Vital and cardiac transplant status data were
assessed in all 546 subjects enrolled in Fontan 1.
From this original group, subjects who were alive
with a Fontan circulation were approached for
enrollment into the present study. Each center’s
institutional review board approved the protocol.
Written informed consent and assent were
obtained according to local requirements. Ana-
tomic, clinical, and surgical data were collected at
enrollment (November 2009 to May 2011) using
standardized forms. Structured interviews with the
parent/guardian and/or subject were used to assess
current clinical state, socioeconomic status, family
functioning, and access to health care. Vital status
was assessed by either contact or by search of the
social security death index annually following
enrollment.
Measures of Functional Health Status and Quality
of Life
The Child Health Questionnaire (CHQ), which
includes questionnaires for both the child and the
parent, was used for subjects ≤18 years. In subjects
aged ≥19 years, functional status was measured
with the Short-FormHealth Survey version 2 (SF-
36).10 The Pediatric Quality of Life Inventory
(Peds-QL) with a self-report and a parallel parent
proxy report was used to assess quality of life.11,12
In addition, a cardiac disease-speciﬁc module of
the Peds-QL was administered. Pediatric Quality
of Life Inventory age group versions (8–12 years
old, 13–18 years old, and 19–25 years old) have
almost identical questions with minor differences
in language. To preserve sample size and after con-
sultation with experts (personal communication
with J. Varni, MD, July, 2013), we combined these
versions for analytic purposes.
Statistical Methods
The relationship between transplant-free survival
and baseline (assessed at Fontan 1) covariates was
examined using Cox proportional hazards regres-
sion modeling. Follow-up time was deﬁned as the
time from Fontan 1 medical record review until
either death/transplant or the latest available
assessment of vital/transplant status (at or after
Fontan 2 enrollment). We report hazard ratios
with 95% conﬁdence intervals and P values asso-
ciated with the Wald chi-square test. Statistical
signiﬁcance was considered using a two-sided
critical value of P = .05. The proportional hazards
assumption was evaluated using a supremum test
for nonproportionality based on Martingale
residuals, and interaction terms with time were
considered as appropriate. Key results are illus-
trated using Kaplan–Meier survival plots.
Subsequent analyses compared prespeciﬁed
subgroups deﬁned by ventricular morphology,
Fontan procedure type, and age at enrollment.
Differences in patient outcomes by subgroup
levels were assessed using a regression model
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adjusted for age, gender (if gender mix differed),
and clinical site (for medical history variables and
medication use). For continuous outcomes, mean
values by subgroup were compared using a para-
metric analysis of variance-based test and an
age- and gender-adjusted analysis of covariance.
Additionally, median values by subgroup were
compared using a nonparametric (Wilcoxon or
Kruskal–Wallis) test. If any of these three tests was
signiﬁcant, Bonferroni corrections were calcu-
lated. For binary outcomes, frequencies in the
subgroups were compared using Fisher’s exact test
and a gender- and age-adjusted logistic regression
model. For ordered categorical outcomes, the
presence of a linear trend was assessed using
Mantel-Haenszel test for trend, and a gender- and
age-adjusted cumulative or multinomial logistic
regression was used as appropriate. For interim
medical history events, mean incidence rates of the
event were compared by subgroup using Poisson
regression. To explore differences related to age,
we divided the study population into two groups
(younger vs. older). For continuous variables and
instruments validated across all ages, e.g. medical
history and Peds-QL, 18 years was selected as a
cutoff value. The cutoff of 18 was selected as this
age is used frequently to deﬁne an adult and this
provided similar sized groups for comparison. For
instruments validated only in children (e.g.,
CHQ-PF50 and CHQ-CF87), 16 years was
selected as a cutoff. Similarly, for forms validated
only in adults (e.g., SF-36), the adult cohort
(deﬁned as ≥19 years) was divided into two
roughly similar sized groups; those < or ≥22.5
years. All analyses were performed using SAS sta-




From the original Fontan 1 cohort of 546 subjects,
29 (5%) either died (n = 16) or were transplanted
(n = 13) prior to Fontan 2 enrollment and 1 subject
died after enrollment. Additionally, one subject
underwent a conversion to a two-ventricle circu-
lation prior to Fontan 2 enrollment. The 516 sur-
viving subjects with a Fontan circulation were
considered eligible for the Fontan 2 study and 427
subjects (83%) enrolled. Thirteen subjects (2.5%)
were lost to follow-up and 76 subjects (15%) did
not give consent. The enrolled subjects were com-
pared with the eligible but non-consenting sub-
jects who either were lost to follow-up or refused
consent. Enrolled subjects were younger (18.4 ±
3.4 vs. 19.6 ± 3.3 years, P = .002) and had a lower
proportion of males (58% vs. 71%, P = .02). After
adjustment for age and gender, enrollees came
from households with a higher income level and
higher level of maternal education (P < .001 for
both). No differences were identiﬁed in any
cardiac characteristics or laboratory measures
from Fontan 1.
Died/Transplanted vs.Transplant-free Survivors
Vital status assessment data were collected on all
of the original 546 subjects except the 13 who
were lost to follow-up. The social security death
index was searched for the 13 lost-to-follow-up
subjects and none were reported to have died.
The 502 transplant-free survivors through the
end of follow-up were compared with the 30 who
died or had heart transplants (1 subject died after
enrolling in Fontan 2) (Figure 1). There were no
differences in the risk of death/transplant based
on age, dominant ventricular morphology, or
type of Fontan procedure. On univariate analysis,
the risk of death or transplant after Fontan 1 was
signiﬁcantly associated with the following mea-
surements obtained at Fontan 1: a poorer CHQ-
PF50 physical summary score (36.6 ± 13.6 vs.
45.8 ± 11.5, P < .01) (Figure 2A), increased end
systolic and end diastolic volume z-scores (P <
.02 for both), a higher brain natriuretic peptide
(BNP) concentration value (P = .04) (Figure 2B),
Figure 1. Transplant-free survival since Fontan 1 (with
95% confidence intervals) in a cohort of 532 subjects with
complete follow-up data. For improved resolution, the scale
on the y-axis is limited to 0.9–1.0.
Atz et al.E32
Congenit Heart Dis. 2015;10:E30–E42
and inability to perform an exercise test (P < .05).
The hazard of death/transplant for subjects with
both an elevated BNP (>21 pg/mL) and a low
physical summary score (<44) was 6.2 (2.9–13.5)
times higher than for the rest of the cohort
(Figure 2C).
Fontan 2 Cohort Characteristics
The 427 enrolled subjects were 18.4 ± 3.4 years
old at Fontan 2 enrollment. The mean follow-up
time was 6.8 ± 0.4 years from Fontan 1 and 15.2 ±
3.4 years after Fontan surgery. Since Fontan
surgery, 119 subjects (28%) had additional cardiac
surgery, with 55% of these (n = 66) occurring in
the interim between Fontan 1 and Fontan 2.
During the interim period, 10 subjects underwent
a Fontan conversion. The most common surgical
procedure performed since Fontan 1 involved
placement or replacement of implantable elec-
tronic devices, which were currently in place in
13% (n = 56). A cardiac catheter intervention
occurred in 242 subjects (57%); 32% of these (n =
78) took place after Fontan 1. Since the Fontan
procedure, stroke was reported in 2%, seizures in
5%, thrombosis in 9%, cirrhosis in 4%, plastic
bronchitis in 0.5%, and protein-losing enteropa-
thy in 7%. Arrhythmia receiving treatment or
intervention since the Fontan surgery occurred in
118 (28%) subjects; 58% of these (n = 68) hap-
pened since Fontan 1.
Mean CHQ-PF50 summary scores for the 264
subjects <19 years were signiﬁcantly lower than
those of historical, healthy, control subjects13 (44 ±
12 vs. 53 ± 9 for physical, and 48 ± 12 vs. 51 ± 9
for psychosocial summary scores, each P < .01).
However, individual scores were within the 95th
percentile conﬁdence interval of the mean of
historical healthy controls in 78% of subjects for
the physical summary score and in 88% for the
psychosocial summary score. (Figure 3) Mean
summary scores among the 153 adult subjects
completing the SF-36 were not different (P > .1)
from those for healthy controls: the aggregate
physical score was 50 ± 8; 97% of Fontan 2 sub-
jects scored within the 95th percentile conﬁdence
interval for the mean of healthy control subjects.
The aggregate mental score was 49 ± 12 with 91%
of Fontan 2 subjects scoring within the 95th per-
centile conﬁdence interval of the expected mean
score of 50 (Figure 4).
Association with Ventricular Dominance
The ventricular morphology was left dominant in




Figure 2. Association of interim (between Fontan 1 and
Fontan 2) transplant-free survival with CHQ-PF50 physical
summary score (A); serum BNP level (B); and both (C). For
improved resolution, the scale on the y-axis is limited to
0.75–1.0. BNP, brain natriuretic peptide; CHQ, Child Health
Questionnaire.
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the 427 enrolled subjects (Table 1). Subjects with
a dominant right ventricle (RV) used a greater
number of medicines. Those with a dominant RV
were prescribed angiotensin-converting enzyme
(ACE) inhibitors more frequently compared with
the others, even after adjustments were made for
differences by clinical center. Parents of subjects
with a dominant RV reported a lower physical
functioning domain score on the CHQ-PF50,
although there was no difference in the analo-
gous domain reported by the subjects themselves
on the CHQ-CF87. Similarly, only a single
domain on either the parent or subject, Peds-QL
differed by ventricular dominance. Subjects (but
not their parents) with a dominant RV reported a
better “treatment” score compared with those
with mixed ventricular morphology. Differences
were observed in 8 of the 10 scales of the SF-36
among adult subjects with those with left ven-
tricular morphology scoring better and those
with mixed ventricular morphology scoring the
poorest.
A








Figure 3. The distribution of Child Health Questionnaire-Parent Form (CHQ-PF50) physical (A) and psychosocial (B)
summary scores from 257 children enrolled in the Fontan 2 Study. The line shows the normal distribution for the general
population. SD, standard deviation.
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Association with Age
Younger subjects (<18 years, n = 225) were less
likely to have suffered from stroke both since their
Fontan procedure and in the interim between
Fontan 1 and Fontan 2. Interim development of
thrombosis since Fontan 1 was more likely in the
older (≥18 years, n = 202) cohort. Younger subjects
were more likely to be prescribed ACE inhibitors.
For the Peds-QL that included all ages, only the
treatment scale differed, being better among the
younger cohort.
Because the CHQ is validated only in children
≤19 years old, we compared results of these tests
between a younger group of 120 subjects
<16 years and an older group of 144 subjects
16–19 years old. The mental health, self-esteem,
and general health perception scales were higher
(better) among the younger group as reported by
both the subjects and their parents. We also com-
pared a younger adult group comprising 76 adult
subjects 19 to <22.5 years with an older group of











Figure 4. The distribution of Short Form 36 (SF-36) physical (A) and mental aggregate (B) scores from 153 adults enrolled
in the Fontan 2 Study. The line shows the normal distribution for the general population. SD, standard deviation.
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Table 1. Patient Characteristics by Ventricular Dominance
Total (n = 427) Left (n = 214) Right (n = 141) Mixed (n = 72) P value*
Age, years Mean ± SD 18.4 ± 3.4 18.7 ± 3.3 17.9 ± 3.3 18.5 ± 3.7 .15†
Male n (%) 249 (58%) 119 (56%) 94 (67%) 36 (50%) .05‡
Post-Fontan surgery medical review record n 426 214 140 72
Age, years Mean ± SD 18.6 ± 3.4 18.9 ± 3.4 18.1 ± 3.4 18.8 ± 3.7 .14
Follow-up time, years Mean ± SD 15.2 ± 3.4 15.5 ± 3.3 14.8 ± 3.4 15.1 ± 3.4 .38
Cardiac surgical procedure n (%) 119 (28%) 70 (33%) 36 (26%) 13 (18%) .04
Cardiac cath intervention n (%) 242 (57%) 118 (55%) 84 (60%) 40 (56%) .51
Stroke n (%) 10 (2%) 5 (2%) 5 (4%) 0 (0%) .07
Seizure n (%) 23 (5%) 11 (5%) 11 (8%) 1 (1%) .05
Thrombosis n (%) 39 (9%) 24 (11%) 11 (8%) 4 (6%) .47
Arrhythmia n (%) 118 (28%) 62 (29%) 32 (23%) 24 (33%) .68
Other important complications n (%) 215 (50%) 98 (46%) 73 (52%) 44 (61%) .25
Protein-losing enteropathy n (%) 30 (7%) 11 (5%) 8 (6%) 11 (15%) .15
Cirrhosis diagnosis n (%) 15 (4%) 5 (2%) 7 (5%) 3 (4%) .24
Plastic bronchitis diagnosis n (%) 2 (0.5%) 1 (0.5%) 1 (1%) 0 (0%) .99
IED in place n (%) 56 (13%) 38 (18%) 15 (11%) 3 (4%) .002
Clinical assessment
Percentile height for age Mean ± SD 36.7 ± 30.9 37.5 ± 31.4 34.3 ± 30.2 39.7 ± 31.5 .60
Height-for-age z-score Mean ± SD −0.6 ± 1.4 −0.6 ± 1.4 −0.8 ± 1.5 −0.4 ± 1.5 .37
Percentile weight for age Mean ± SD 45.1 ± 33.8 44.5 ± 33.5 44.4 ± 35.7 48.7 ± 30.5 .81
Weight-for-age z-score Mean ± SD −0.3 ± 1.6 −0.3 ± 1.5 −0.4 ± 1.7 −0.1 ± 1.2 .68
BMI-for-age z-score Mean ± SD −0.0 ± 1.3 0.0 ± 1.2 −0.1 ± 1.4 0.1 ± 1.1 .95
NYHA heart failure classification .14
Class I n (%) 234 (55%) 125 (58%) 74 (53%) 35 (49%)
Class II n (%) 119 (28%) 57 (27%) 42 (30%) 20 (28%)
Class III n (%) 49 (12%) 22 (10%) 15 (11%) 12 (17%)
Class IV n (%) 24 (6%) 10 (5%) 9 (6%) 5 (7%)
Medications
Number of medications n (%) .002
0 n (%) 45 (11%) 27 (13%) 7 (5%) 11 (15%)
1 n (%) 99 (23%) 60 (28%) 25 (18%) 14 (19%)
≥2 n (%) 282 (66%) 127 (59%) 108 (77%) 47 (65%)
Mean ± SD 2.9 ± 2.6 2.5 ± 2.4 3.4 ± 2.9 2.8 ± 2.5 <.001
ACE Inhibitors n (%) 226 (53%) 92 (43%) 102 (73%) 32 (44%) <.001
CHQ-PF50—parent report n 264 124 98 42
Age, years Mean ± SD 16.3 ± 1.6 16.3 ± 1.6 16.3 ± 1.8 16.0 ± 1.4 .48
Physical summary score Mean ± SD 44 ± 12 43 ± 13 44 ± 12 47 ± 9 .11
Psychosocial summary score Mean ± SD 48 ± 12 49 ± 10 47 ± 12 48 ± 13 .61
Global health scale Mean ± SD 77 ± 21 77 ± 21 76 ± 21 83 ± 20 .22
Physical functioning scale Mean ± SD 81 ± 21 82 ± 21 78 ± 23 88 ± 13 .01
CHQ-CF87—child report n 255 121 93 41
Age, years Mean ± SD 16.3 ± 1.6 16.3 ± 1.5 16.3 ± 1.8 16.0 ± 1.4 .46
Global health scale Mean ± SD 76 ± 21 77 ± 20 75 ± 24 76 ± 21 .52
Physical functioning scale Mean ± SD 87 ± 14 88 ± 14 86 ± 16 90 ± 10 .18
Peds-QL—parent report n 262 123 97 42
Age, years Mean ± SD 16.2 ± 1.6 16.3 ± 1.6 16.2 ± 1.8 16.0 ± 1.4 .48
4.0 generic core scales
Physical functioning score Mean ± SD 72 ± 21 72 ± 21 71 ± 22 75 ± 20 .45
Emotional functioning score Mean ± SD 72 ± 20 72 ± 20 71 ± 21 73 ± 19 .70
Social functioning score Mean ± SD 71 ± 25 73 ± 25 67 ± 25 74 ± 23 .09
School functioning score Mean ± SD 64 ± 21 64 ± 22 63 ± 21 67 ± 18 .76
Psychosocial health summary score Mean ± SD 69 ± 18 70 ± 18 67 ± 19 72 ± 17 .27
Physical health summary score Mean ± SD 72 ± 21 72 ± 21 71 ± 22 75 ± 20 .45
Total generic score of pediatric quality of life Mean ± SD 70 ± 18 71 ± 18 68 ± 18 73 ± 16 .27
3.0 cardiac module
Heart problems and treatment score Mean ± SD 72 ± 19 70 ± 20 73 ± 19 75 ± 20 .28
Treatment score Mean ± SD 89 ± 13 90 ± 14 88 ± 13 90 ± 11 .31
Perceived physical appearance score Mean ± SD 78 ± 23 78 ± 23 77 ± 25 82 ± 19 .31
Treatment anxiety score Mean ± SD 76 ± 26 76 ± 27 76 ± 25 74 ± 28 .99
Cognitive problems score Mean ± SD 60 ± 26 62 ± 26 57 ± 27 64 ± 24 .25
Communication score Mean ± SD 71 ± 29 68 ± 32 73 ± 28 76 ± 23 .22
Peds-QL—child report n 408 206 132 70
Age, years Mean ± SD 18.5 ± 3.4 18.8 ± 3.4 18.1 ± 3.4 18.7 ± 3.7 .23
4.0 generic core scales
Physical functioning score Mean ± SD 75 ± 18 76 ± 18 73 ± 18 74 ± 18 .22
Emotional functioning score Mean ± SD 74 ± 21 74 ± 20 74 ± 21 72 ± 22 .68
Social functioning score Mean ± SD 78 ± 20 80 ± 18 76 ± 23 78 ± 21 .13
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in any of the 10 reported scales of the SF-36
(Table 2).
Association with Fontan Type
Fontan procedure types included atriopulmonary
connection (APC, n = 54), total cavopulmonary
connection intracardiac lateral tunnel (LT, n =
251), and total cavopulmonary connection extrac-
ardiac conduit (ECC, n = 111). After adjustment
for age, subjects with an APC were less likely to
have had a cardiac catheter based intervention
since the Fontan procedure (31% APC vs. 59%
LT vs. 65% ECC), P = .004. However, catheter
interventions since Fontan 1 were not different
between groups, P = .4. The incidence of arrhyth-
mia since the Fontan procedure was higher in
APC subjects (44% APC vs. 28% LT vs. 19%
ECC), but this was not signiﬁcant after accounting
for age, P = .4. However, the development of new
arrhythmia requiring treatment in the interim
period between Fontan 1 and Fontan 2 was sig-
niﬁcantly higher in APC subjects even after
accounting for age (30% APC vs. 16% LT vs. 10%
ECC), P = .049.
Characteristics of Health Care
There was a signiﬁcant difference between sites
for the frequency of a secondary source of insur-
ance (P < .001). The rate was much higher for
Canadian subjects (79%) than for those from US
sites (10–26%). The vast majority of subjects
(96%) have visited a cardiologist within the past
2 years. We compared 295 subjects with a visit
frequency of ≤1 visit per year with 125 subjects
with ≥2 visits per year. In multivariable modeling,
the only associated factor for more frequent visits
was clinical site (P < .001, R2 = 0.10). The most
prevalent medical services reported by subjects
were dental care (92%), ophthalmology (62%),
educational support (36%), gynecology (32% of
the females), mental health (19%), and dermatol-
ogy and neurology (15% each) (Table 3).
Discussion
Longitudinal studies that involve children with
chronic diseases transitioning to adulthood are
uncommon. This is the largest report of a pro-
spectively followed multicenter cohort of child-
Table 1. Continued
Total (n = 427) Left (n = 214) Right (n = 141) Mixed (n = 72) P value*
School functioning score Mean ± SD 70 ± 20 71 ± 19 71 ± 22 68 ± 19 .71
Psychosocial health summary score Mean ± SD 74 ± 17 75 ± 15 73 ± 19 73 ± 17 .46
Physical health summary score Mean ± SD 75 ± 18 76 ± 18 73 ± 18 74 ± 18 .22
Total generic score of pediatric quality of life Mean ± SD 74 ± 16 75 ± 15 73 ± 18 73 ± 17 .29
3.0 cardiac module
Heart problems and treatment score Mean ± SD 68 ± 19 68 ± 19 70 ± 20 67 ± 21 .97
Treatment score Mean ± SD 89 ± 13 89 ± 14 92 ± 9 84 ± 17 .002
Perceived physical appearance score Mean ± SD 77 ± 24 77 ± 24 78 ± 24 77 ± 23 .90
Treatment anxiety score Mean ± SD 81 ± 24 81 ± 24 83 ± 24 78 ± 24 .74
Cognitive problems score Mean ± SD 67 ± 23 69 ± 22 65 ± 24 66 ± 22 .25
Communication score Mean ± SD 73 ± 25 72 ± 24 74 ± 27 73 ± 25 .96
SF-36—adult n 153 85 39 29
Age, years Mean ± SD 22.4 ± 1.9 22.3 ± 1.8 22.4 ± 2.3 22.6 ± 1.9 .81
Aggregated physical score, norm based Mean ± SD 50 ± 8 51 ± 8 49 ± 9 48 ± 8 .11
Aggregated mental score, norm based Mean ± SD 49 ± 12 51 ± 11 49 ± 10 41 ± 14 .001
Physical functioning (transformed scale) Mean ± SD 80 ± 20 84 ± 19 77 ± 21 75 ± 20 .04
Role—physical (transformed scale) Mean ± SD 81 ± 24 86 ± 21 80 ± 25 68 ± 29 .003
Bodily pain (transformed scale) Mean ± SD 77 ± 23 82 ± 19 78 ± 23 63 ± 26 <.001
General health (transformed scale) Mean ± SD 63 ± 22 64 ± 22 63 ± 24 61 ± 21 .78
Vitality (transformed scale) Mean ± SD 62 ± 21 65 ± 19 60 ± 25 54 ± 19 .03
Social functioning (transformed scale) Mean ± SD 81 ± 24 86 ± 20 79 ± 22 66 ± 31 <.001
Role—emotional (transformed scale) Mean ± SD 82 ± 26 87 ± 23 84 ± 21 67 ± 33 <.001
Mental health (transformed scale) Mean ± SD 73 ± 20 77 ± 18 73 ± 19 62 ± 22 .002
Socioeconomic status n 420 211 139 70
Hollingshead Score Mean ± SD 44 ± 15 42 ± 14 45 ± 14 47 ± 16 .04
*ANCOVA for means; logistic regression for percentages; Poisson regression for incidence rates; adjusted for age and sex.
Medical review and medications are also adjusted for clinical site.
†Adjusted for sex only.
‡Adjusted for age only.
ACE, angiotensin-converting enzyme; BMI, body mass index; cath, cardiac catheterization; CHQ-CF87, Child Report Child Health Questionnaire; CHQ-PF50,
Parent Report Child Health Questionnaire; IED, implanted electronic device; NYHA, New York Heart Association Heart Failure Class; Peds-QL, The Pediatric
Quality of Life Inventory; SD, standard deviation; SF-36, Short-Form Health Survey version 2. P values <0.05 noted in bold font.
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ren with univentricular physiology palliated with
a Fontan procedure. We found that only 2%
were lost to follow-up and 83% of the original
cohort were willing to participate. Older patients
and males were less likely to agree to participate.
This is consistent with challenges that are faced
in the transition of clinical care from pediatric
cardiologists to adult congenital heart disease
specialists.14
We found 95% interim transplant-free survival
over an average of 7 years of follow-up since
enrollment in the Fontan 1 study. Those with
poorer results during the baseline assessment at
Fontan 1 were more likely to have died or be
transplanted. Speciﬁcally, we found death or trans-
plant to be associated with worse performance on
previously administered CHQ-PF50 physical
summary score, a more dilated ventricle as
Table 2. Associations with Age
Younger (Age < 18) Older (Age > 18) P Value*
Medical review from Fontan 1 to Fontan 2 n = 212 n = 214
Follow-up time, years Mean ± SD 6.8 ± 0.4 6.9 ± 0.5 .32
Cardiac surgical procedure n (%) 29 (14%) 37 (17%) .36
Cardiac cath intervention n (%) 38 (18%) 40 (19%) .88
Stroke n (%) 0 (0%) 3 (1%) .04
Seizure n (%) 4 (2%) 11 (5%) .07
Thrombosis n (%) 2 (1%) 12 (6%) .005
Arrhythmia n (%) 26 (12%) 42 (20%) .06
Other important complications n (%) 74 (35%) 84 (39%) .49
On heart transplant waiting list n (%) 0 (0%) 1 (1%) .99
IED in place n (%) 22 (10%) 34 (16%) .11
Medical review since Fontan surgery n = 212 n = 214
Follow-up time, years Mean ± SD 12.8 ± 1.7 17.8 ± 2.8 <.001
PLE n (%) 13 (6%) 17 (8%) .85
Cirrhosis n (%) 3 (1%) 12 (6%) .07
Plastic bronchitis n (%) 1 (0.5%) 1 (0.5%) .81
Clinical assessment n = 216 n = 210
Percentile height for age Mean ± SD 36 ± 31 40 ± 30 .32
Height-for-age z-score Mean ± SD −0.7 ± 1.5 −0.5 ± 1.2 .27
Percentile weight for age Mean ± SD 45 ± 34 46 ± 34 .72
Weight-for-age z-score Mean ± SD −0.4 ± 1.6 −0.2 ± 1.6 .55
BMI-for-age z-score Mean ± SD 0.0 ± 1.3 0.0 ± 1.3 .94
NYHA heart failure classification n (%) .25
Class I 123 (57%) 111 (53%)
Class II 63 (30%) 56 (27%)
Class III 22 (10%) 27 (13%)
Class IV 8 (4%) 16 (7%)
Number of medications n (%) .22
0 18 (8%) 27 (13%)
1 55 (25%) 44 (21%)
≥2 145 (67%) 137 (66%)
ACE inhibitors n (%) 127 (58%) 99 (48%) .03
Peds-QL—subject report n = 207 n = 201
4.0 generic core scales
Physical functioning score Mean ± SD 76 ± 17 73 ± 20 .16
Emotional functioning score Mean ± SD 74 ± 20 73 ± 21 .51
Social functioning score Mean ± SD 78 ± 20 78 ± 21 .94
School functioning score Mean ± SD 70 ± 19 71 ± 21 .85
Psychosocial health summary score Mean ± SD 74 ± 16 74 ± 18 .74
Physical health summary score Mean ± SD 76 ± 17 73 ± 20 .16
Total generic score of pediatric quality of life Mean ± SD 75 ± 15 74 ± 17 .41
3.0 cardiac module
Heart problems and treatment score Mean ± SD 70 ± 19 66 ± 20 .06
Treatment score Mean ± SD 91 ± 11 87 ± 15 .001
Perceived physical appearance score Mean ± SD 79 ± 22 75 ± 26 .13
Treatment anxiety score Mean ± SD 81 ± 24 81 ± 24 .86
Cognitive problems score Mean ± SD 69 ± 22 65 ± 24 .08
Communication score Mean ± SD 73 ± 24 72 ± 26 .65
Socioeconomic status n = 214 n = 206
Hollingshead score Mean ± SD 45 ± 14 43 ± 15 .19
Median (IQR) 47 (35, 56) 45 (33, 55) .19
*ANOVA for means; Fisher’s exact test for frequencies.
ACE, angiotensin-converting enzyme; BMI, body mass index; cath, cardiac catheterization; IED, implanted electronic device; IQR, interquartile range; NYHA, New
York Heart Association Heart Failure Class; Peds-QL, The Pediatric Quality of Life Inventory; PLE, protein-losing enteropathy; SD, standard deviation. P values
<0.05 noted in bold font.
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measured by echocardiography, and higher mea-
sured BNP assessed at Fontan 1. Previous studies
examining vital status over time for Fontan survi-
vors and predictors of death or transplant have
been limited to single center reports that span
large time periods (e.g., 25 years)15 or have
included a much shorter length of follow-up (e.g.,
<2years).16 Our data show a slightly lower inci-
dence of death and transplant than a previous
study of 321 surviving Fontan subjects with a mean
age of 21 years.16
There have been concerns that patients with a
Fontan circulation are destined to have an increas-
ing risk over time for death or heart transplan-
tation17 as well as a decline in ventricular perfor-
mance and health status.18 Rates of decline have
been speculated to be greater among those with
dominant RV morphology.19,20 We did not ﬁnd RV
dominant subjects to have a greater likelihood of
death or transplant over the period of study. This
is in contrast to a cohort of earlier era Fontan
subjects born before 1985 and followed for a
median of 12 years in whom a 10-fold risk of heart
failure death was seen in those with a morphologic
RV.15 We did ﬁnd an increase in the use of ACE
inhibitors in both younger subjects and those with
a dominant RV. We speculate this is a difference in
practice patterns that exists despite the lack of
evidence to suggest beneﬁt.21 Although no impor-
tant differences in quality of life or functional
health status were related to ventricular domi-
nance among the children in our study, we did ﬁnd
higher (better) scores in 8 of 10 scales from the
SF-36 among the adults with left ventricular
dominance.
The strength of this current study is its uniform
median follow-up period for all subjects. This
allowed us to compare outcomes since the Fontan
completion (median 15 ± 3.4 years) as well as in
the interim since Fontan 1 (6.8 ± 0.4 years). Sub-
jects with an APC type of Fontan had fewer inter-
ventional catheter procedures between Fontan
completion and Fontan 1 assessment compared
with other Fontan types, a difference that was not
observed in the interim period since assessment at
Fontan 1. This is likely due to a much higher rate
of surgical fenestration in non-APC Fontan types
with planned procedures to close these in the ﬁrst
year or so after Fontan surgery.22 We were able to
conﬁrm previous reports that ongoing risk of
development of arrhythmia is greater among sub-
jects with an APC compared with other Fontan
types.23
Quality-of-life studies complement mortality
and morbidity data by taking physical, psychologi-
cal, and social factors into consideration.24
Although the mean CHQ-PF50 physical summary
score was lower than those of healthy control sub-
jects, a large majority of adolescent subjects (as
reported by a parent) continue to score within the
normal range. Comparisons among adults in our
cohort evaluated by the SF-36 reveal even fewer
differences compared with self-reported historic
norms. These results may be explained by
coping mechanisms in the adult subjects resulting
in a higher appreciation of health status, which
is exempliﬁed by higher scores.25 This may also
reﬂect the known discordance when comparing
parent-completed surveys to subject-completed
surveys.26
Table 3. Characteristics of Health Care
n (%)
Health insurance (n = 420)
Yes 406 (97%)
No 14 (3%)
Primary insurance type (n = 406)
Private 214 (53%)
Public 192 (47%)
Secondary source of health insurance (n = 405)
Yes 134 (33%)
No 271 (67%)
Visited a cardiologist in the past 2 years (n = 420)
Yes 404 (96%)
No 16 (4%)
Frequency of cardiologist visits (n = 404)
Less than once a year 41 (10%)
Once a year 238 (59%)
Twice a year 85 (21%)
More than twice a year 40 (10%)




Medical services received in the past 2 years
(n = 420)
Dental care 385 (92%)
Ophthalmology 261 (62%)
Education support 150 (36%)
Obstetrician/gynecologist (n = 203)† 64 (32%)




Rehabilitation/physical therapy 56 (13%)
Otolaryngology 43 (10%)
Pulmonology 42 (10%)
Occupational therapy 37 (9%)
Speech therapy 37 (9%)
Endocrine 27 (6%)
Nutrition 27 (6%)
Allergy services 26 (6%)
Renal 18 (4%)
Any other 70 (17%)
*Question only asked of subjects ≥16 years.
†Question only asked of female subjects.
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Because of the nature of this observational
cohort, we cannot exclude the possibility that the
lowest performing subjects are less likely to
survive with a Fontan circulation into adulthood.
A signiﬁcant limitation illustrated in our study
is that instruments to study functional health out-
comes are validated only for speciﬁc age groups.
There is not a single instrument that includes the
full age range of subjects who are transitioning
from the teenage years to adulthood. The CHQ
produces scores for 14 domains and two summary
scores (physical functioning and psychosocial
functioning). Our results for the mean physical
summary score for Fontan subjects (44 ± 12) are
similar to those subjects with asthma (48 ± 7),
juvenile rheumatoid arthritis (42 ± 14), and epi-
lepsy (48 ± 14). The same is true for the psycho-
social summary scores, 48 ± 12 in our Fontan
group, asthma (52 ± 8), epilepsy (47 ± 12), and
attention deﬁcit disorder (37 ± 11).13 The SF-36
is a multipurpose, 36-item adult health survey
that yields an 8-scale proﬁle of functional health
and well-being scores as well as psychometrically
based physical and mental health summary mea-
sures. The results of our cohort of adult subjects
showed similar scores when compared with a
recent study involving 54 Danish subjects with a
Fontan circulation.27 A recent systematic review
of quality-of-life studies in adult congenital heart
disease patients suggests that, in general, quality
of life is compromised in the physical domains
compared with norms and less so in relation to
psychosocial and environmental/occupational
domains.28 These ﬁndings are supported by our
results. Correlations are needed between indi-
vidual instruments that assess functional health
status and quality of life across the transition from
child to adult.
The results of this study must be viewed in light
of certain limitations. The original Fontan 1
cohort was by necessity a subset of Fontan survi-
vors. The time frame between Fontan 1 and 2 may
have been a period of relative clinical stability
and too short to observe meaningful changes in
functional health status and medical conditions. As
stated previously, there are no measurements of
functional health status, which are validated across
the full age range of the subjects being studied.
Comparisons between younger and older groups
of subjects divided the cohort into similar-sized
groups. If this separation was made in different
ways, our ﬁndings related to age might be differ-
ent. The present study was limited to assessment
of functional health status and interim medical
history. Our assessment was also restricted to the
85% of eligible Fontan 1 survivors who agreed to
participate in this follow-up study. Repeat labora-
tory testing and comparisons of these measures
over time, which were not assessed at Fontan 2,
will be the subject of future research.
This is the largest report of a prospectively
followed multicenter cohort of children with uni-
ventricular physiology palliated with a Fontan
procedure and provides a contemporary overview
of vital status, functional health status, and interim
medical history in current survivors of the Fontan
procedure. Incidence of death or transplantation is
low and associated with prior poor functional
health status and certain measures of ventricular
performance. Functional health status was within
normal range in the majority of subjects. Data
from this study will permit useful comparisons
with the data from single ventricle subjects being
followed prospectively from birth in other studies.
Continued longitudinal investigation into adult-
hood is necessary to better understand these
patients and improve their long-term outcomes
and functional health status.
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